In Mondis v. LG, the Federal Circuit ruled that the patent's written description failed to support amended claims, invalidating key computer display claims.
The Federal Circuit revived UC Berkeley’s claim to key CRISPR gene editing patents, directing the USPTO to reconsider if its findings predate Broad Institute’s.
FDA declined to appeal a court ruling invalidating its 2024 LDT rule, concluding its push to expand regulatory control over lab-developed tests.
In Wuhan Healthgen Biotechnology Corp. v. U.S. ITC, the Federal Circuit upheld an ITC ruling that Ventria Bioscience met the domestic industry requirement despite a modest investment in a patented bio
